Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to investigate whether dexmedetomidine could suppress catecholamine release into peripheral blood to prevent PSH attacks and to achieve neuroprotection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xiangya Hospital of Central South University
• Treatments: Dexmedetomidine; Midazolam

Criteria

Inclusion Criteria:

1. Age: 18-70 years

2. Moderate or severe traumatic brain injury

3. GCS≤12

4. Diagnosed by CT

5. No catecholamines (such as dopamine, adrenaline, norepinephrine) have been used before admission

6. Have a clear history of head trauma

7. Non-open traumatic brain injury

Exclusion Criteria:

1. Severe liver dysfunction (Child-Pugh B or C)

2. Severe renal dysfunction (serum creatinine > 445 mmol / L or blood urea nitrogen > 20 mmol / L)

3. Hemodynamic instability when entering the ICU (heart rate <50 beats / min or hypotension, SBP <90mmHg or MAP <65mmHg)

4. Deaths within 72 hours after entering the ICU

5. Severe multiple injuries (ISS≥25 points)

6. Have central nervous system diseases (such as hypoxic ischemic encephalopathy, stroke, brain tumors, etc.)

7. Allergic to dexmedetomidine or midazolam

8. Observed with the results of disease interference test (such as pheochromocytoma, etc.)

9. In pregnancy or lactation

10. Receiving hypothermia treatment

11. Are participating in other drug research or clinical trials